
Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Cluster Headache Syndrome (Cluster Headache) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.
Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 3, 4, 6 and 3 respectively.
Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.
Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 3, 4, 6 and 3 respectively.
Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
Amgen Inc
Amneal Pharmaceuticals Inc
Better Life Pharmaceuticals Inc
Biohaven Pharmaceutical Holding Company Ltd
Bright Minds Biosciences Inc
CCH Pharmaceuticals ApS
Ceruvia Lifesciences LLC
Clexio Biosciences Ltd
Crossject SA
Eli Lilly and Co
H. Lundbeck AS
Havn Life Sciences Inc
Mind Medicine MindMed Inc
NeuroPharm Inc
Psirenity Inc
Shackelford Pharma Inc
Winston Pharmaceuticals Inc
Xgene Pharmaceutical Inc
Zosano Pharma Corp
Companies Mentioned
Amgen Inc
Amneal Pharmaceuticals Inc
Better Life Pharmaceuticals Inc
Biohaven Pharmaceutical Holding Company Ltd
Bright Minds Biosciences Inc
CCH Pharmaceuticals ApS
Ceruvia Lifesciences LLC
Clexio Biosciences Ltd
Crossject SA
Eli Lilly and Co
H. Lundbeck AS
Havn Life Sciences Inc
Mind Medicine MindMed Inc
NeuroPharm Inc
Psirenity Inc
Shackelford Pharma Inc
Winston Pharmaceuticals Inc
Xgene Pharmaceutical Inc
Zosano Pharma Corp
Table of Contents
66 Pages
- Introduction
- Global Markets Direct Report Coverage
- Cluster Headache Syndrome (Cluster Headache) - Overview
- Cluster Headache Syndrome (Cluster Headache) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Cluster Headache Syndrome (Cluster Headache) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cluster Headache Syndrome (Cluster Headache) - Companies Involved in Therapeutics Development
- Amgen Inc
- Amneal Pharmaceuticals Inc
- Better Life Pharmaceuticals Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Bright Minds Biosciences Inc
- CCH Pharmaceuticals ApS
- Ceruvia Lifesciences LLC
- Clexio Biosciences Ltd
- Crossject SA
- Eli Lilly and Co
- H. Lundbeck AS
- Havn Life Sciences Inc
- Mind Medicine MindMed Inc
- NeuroPharm Inc
- Psirenity Inc
- Shackelford Pharma Inc
- Winston Pharmaceuticals Inc
- Xgene Pharmaceutical Inc
- Zosano Pharma Corp
- Cluster Headache Syndrome (Cluster Headache) - Drug Profiles
- BETR-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CLE-500 - Drug Profile
- Product Description
- Mechanism Of Action
- dihydroergotamine mesylate (DHE) - Drug Profile
- Product Description
- Mechanism Of Action
- eptinezumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- erenumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- galcanezumab - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ketamine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- lysergic acid diethylamide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NYPRG-101 - Drug Profile
- Product Description
- Mechanism Of Action
- psilocybin - Drug Profile
- Product Description
- Mechanism Of Action
- psilocybin - Drug Profile
- Product Description
- Mechanism Of Action
- psilocybin - Drug Profile
- Product Description
- Mechanism Of Action
- rimegepant sulfate ODT - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule for Cluster Headache Syndrome (Cluster Headache) - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Agonize 5-HT2A and 5-HT2C for Pain - Drug Profile
- Product Description
- Mechanism Of Action
- SPID-001 - Drug Profile
- Product Description
- Mechanism Of Action
- sumatriptan - Drug Profile
- Product Description
- Mechanism Of Action
- XG-043 - Drug Profile
- Product Description
- Mechanism Of Action
- zolmitriptan - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- zucapsaicin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Cluster Headache Syndrome (Cluster Headache) - Dormant Projects
- Cluster Headache Syndrome (Cluster Headache) - Discontinued Products
- Cluster Headache Syndrome (Cluster Headache) - Product Development Milestones
- Featured News & Press Releases
- Nov 16, 2021: BetterLife Obtains TD-0148A behavioural pharmacology data confirming its projected non-hallucinogenic property
- Sep 29, 2021: BetterLife obtains TD-0148A receptor binding data for IND-enabling pharmacology studies
- Sep 27, 2021: BetterLife files patent for TD-0148A for treatment of cluster headaches and related disorders
- Jun 07, 2021: Amneal announces Dihydroergotamine (DHE) autoinjector NDA for migraines and cluster headaches
- Feb 25, 2021: Emgality (galcanezumab) now approved for use in Canada for the treatment of episodic cluster headache
- Jun 08, 2020: Phase 2 clinical trial of LSD for Suicide Headaches begins treating patients
- Feb 27, 2020: CHMP adopted a negative opinion for an extension of indication for Emgality
- Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache
- Jun 05, 2019: FDA approves first drug for episodic cluster headaches
- May 02, 2019: Lilly to present new data at AAN 2019 on Emgality (galcanezumab-gnlm) reinforcing breadth of headache disorders portfolio
- Mar 05, 2019: Lilly receives FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for the preventive treatment of Episodic Cluster Headache in Adults
- Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache
- May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
- Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Amgen Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Amneal Pharmaceuticals Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Better Life Pharmaceuticals Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Bright Minds Biosciences Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by CCH Pharmaceuticals ApS, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Ceruvia Lifesciences LLC, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Clexio Biosciences Ltd, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Crossject SA, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Eli Lilly and Co, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by H. Lundbeck AS, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Havn Life Sciences Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Mind Medicine MindMed Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by NeuroPharm Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Psirenity Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Shackelford Pharma Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Winston Pharmaceuticals Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Xgene Pharmaceutical Inc, 2022
- Cluster Headache Syndrome (Cluster Headache) - Pipeline by Zosano Pharma Corp, 2022
- Cluster Headache Syndrome (Cluster Headache) - Dormant Projects, 2022
- Cluster Headache Syndrome (Cluster Headache) - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.